TL-118 - Anti-angiogenic treatment in pancreatic cancer: A case report

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Breuer, Shani ^a   Maimon, Ofra ^a   Appelbaum, Liat ^a   Peretz, Tamar ^a   Hubert, Ayala ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti angiogenic; Gemcitabine; Pancreatic cancer; TL 118

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; TL 118; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CIMETIDINE; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DICLOFENAC; DRUG DERIVATIVE; SALAZOSULFAPYRIDINE; TL-118;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY STENT; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASE REPORT; COMMON BILE DUCT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; PANCREAS CANCER; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VOMITING; WEAKNESS; DRUG COMBINATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; RADIOGRAPHY; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CIMETIDINE; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DICLOFENAC; DRUG COMBINATIONS; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SULFASALAZINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876282544     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0585-9     Document Type: Article

References (15)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17.
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Dhauffert B. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-25.
4. Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165-8. (Epub 2011 Aug 1).
5. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878-86.
6. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advancedpancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-22.
7. Meyers MO, Watson JC. Angiogenesis and hepatic colorectal metastases. Surg Oncol Clin N Am. 2003;12(1):151-63.
8. Murphy JF, Steele C, Belton O, Fitzgerald DJ. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3. Br J Haematol. 2003;121(1):157-64.
9. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79(12):1469-77.
10. Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 1988;24(2):161-7.
11. Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients? A reappraisal of the evidence to date. Digestion. 1999;60(5):415-21.
12. Natori T, Sata M, Nagai R, Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother. 2005;59(1-2):56-60.
13. Mayorek N, Naftali-Shani N, Grunewald M. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS ONE. 2010;5(9):e12715.
14. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119(5):1209-18.
15. Edrei Y, Gross E, Corchia N, Abramovitch R. Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer. 2012;107(4):658-66.